Search in site
BlueWind Medical is an innovative medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has grown to an established company with diverse, creative and committed employees.
BlueWind Medical has successfully completed several clinical studies with excellent results and is focused on bringing this breakthrough neurostimulator to the market.
Our vision is to relieve the pain and suffering, discomfort and disability of all who can benefit from Neurostimulation by miniaturizing and transforming this form of treatment to make it safer, targeted and accessible.
Our mission is to make the quantum leap from a highly-invasive, complex surgical operation to a simple, minimally-invasive procedure that makes effective therapy accessible to physicians and patients alike, but enables a multitude of indications for use.
With our products, patients will have an accessible Neurostimulation therapy earlier in their disease progression - and so, will be spared unnecessary pain and anguish.
Mr. Dan Lemaitre joined BlueWind Medical as Executive Chairman in September 2018.
Dan is also Chairman of Endologix (NYSE: ELGX) an Irvine California company that is focused on aortic disorders with ~$150 million in annual sales and 650 employees.
Dan also serves on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$700 million per annum.
Previously, Mr. Lemaitre was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development.
Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.
Mr. Guri Oron has co-founded Bluewind and been with the company since its inception. He has over 15 years of experience in executive R&D roles, primarily with startups in the medical device field with specific expertise in Neurostimulation technologies. Throughout his career Mr. Oron managed complex R&D projects from their ideation through design, engineering, regulatory and clinical development. Prior to working with BlueWind Medical, Mr. Oron founded and was the CEO of Cybotech, a multinational financial software company. Early on in his career Mr. Oron led the R&D at BrainsGate and served for almost 10 years in the IDF Intelligence Technological Unit. Mr. Oron holds a B.Sc. in Electrical Engineering from Tel Aviv University. He is the lead inventor or co-inventor of numerous patent and patent pending applications.
Mr. Gross is a medical device industry visionary, and one of its most experienced and successful entrepreneurs. Mr. Gross is a founding partner of Rainbow Medical. Mr. Gross first started his professional career as a project manager of the Lavi (IAI Lavi) program for the Israeli Air Force. Since then, Mr. Gross has founded and co-founded over 27 medical device companies providing innovative solutions to significant unmet medical needs. He is the owner of more than 700 patents and patent applications. Mr. Gross holds an MSc degree in aeronautical engineering from the Technion Israel Institute of Technology in Haifa, Israel.
Mr. Cohen brings to BlueWind Medical significant experience in finance, taxes, accounting and M&As. Prior to joining BlueWind (Rainbow) Medical, Mr. Cohen served as group corporate controller for several companies, among them SuperDerivatives Ltd., Verisity Ltd (NASDAQ: VRST). Mr. Cohen spent four years in public accounting at Kesselman & Kesselman (PwC Israel) in Tel Aviv and PricewaterhouseCoopers in San Jose, California, where he was responsible for hi-tech clients. Mr. Cohen is certified as a CPA in Israel, and holds a BA in economics and accounting and an executive MBA, both from Bar-Ilan University.
Mrs. Vaisman is bringing to Bluewind Medical her extensive experience in leading global cross-functional teams in the realization of new medical technologies from the initial concept, through product development, regulatory clearance and commercialization. Prior to joining the Company Mrs. Vaisman was the Director of the Medical Program at Aspect Imaging where she was responsible for the business strategy and product development of a novel Neonatal MRI system. Prior to that, Mrs. Vaisman was the Director of Program Management at Galil Medical (acquired by BTG) directing the development and commercialization of the minimally invasive disposable products. Mrs. Vaisman has also led product and strategic projects at J&J’s Biosense Webster based in California and worked as a consultant to Medical Device start-ups at Ernst & Young. Mrs. Vaisman holds a B.A. (Magna Cum Laude) in Psychology and Science studies from the Hebrew University and an MBA (Summa Cum Laude) from Tel Aviv University.
Mr. Benjamin has over 15 years of experience in medical devices and high-tech industries, in various startup and global corporations (GE Healthcare, Given Imaging, Marvell, Galileo). At GE Healthcare Mr. Benjamin managed a team of system engineers who researched and explored new technologies for future product offering. Prior to GE Healthcare Mr. Benjamin worked at Given Imaging where he managed a highly complex multidisciplinary medical device project through all product life cycle and project aspects from concept through architectural, design, implementation, verification, validation to CE mark registration, pre-FDA clinical trials execution, and product launching. Mr. Benjamin holds a B.Sc. in Electrical Engineering, an M.Sc. in Bio-Medical Engineering (cum laude), and an MBA, all from the Technion – Israeli Institute of Technology.
Dr. Dmochowski is a world-renowned leader in the fields of urology, OAB and incontinence, a recipient of the Zimskind Award and Lifetime Achievement Awards from the Urodynamics Society for his accomplishments in the clinical treatment for incontinence, a Fellow of the American College of Surgeons, a member of the American Urological Association and International Continence Society, and a trustee of the American Board of Urology. An accomplished scholar, Dr. Dmochowski has published over 320 articles, 100 book chapters and 460 abstracts, given over 260 presentations at various national and international meetings, led and participated in dozens of OAB and incontinence studies, is the Editor-in-Chief of NeuroUrology and Urodynamics, and serves on the editorial board for several scientific journals.
Amit Korner VP Clinical Research Mrs. Korner brings over 20 years’ experience in leading clinical research in all phases of development. Prior to joining the company, Mrs. Korner was director of innovative clinical applications in LifeBond and director of clinical operations in Regentis Biomaterials where she was leading clinical activities in surgical orthopedic medical device. Mrs. Korner started her career in the pharmaceutical industry, worked for Quintiles CRO and served as an independent consultant for many years while shifting into medical device and biotech industry. Mrs. Korner holds a B.Sc. in Life Science and a Master’s degree in Public Health (MPH).
Dr. Heesakkers studied Medicine at the Radboud University of Nijmegen. He started his training in Urology in 1993 at the University Hospital Maastricht. In 1997 he successfully defended his thesis titled: ‘Dynamic Urinary Graciloplasty’ at the University of Maastricht. Since 2000 he is a full-time staff urologist at the Department of Urology of the Radboud UMC and consultant at the Rehabilitation Clinic St Maarten in Nijmegen, the Netherlands. He is heading the Unit of Functional Urology and Neurourology. The Unit is officially recognized as national reference center for functional urological disorders and is part of the European Reference Network, a body of the EU. He is the founder and director of the Nijmegen University Pelvic Care Center Isabella. He chairs the Society of Functional and Reconstructive Urology, a body of the Dutch Association of Urology. Dr. Heesakkers is an active member of the EAU, ICS, SUFU and the AUA. He is a faculty member of the European School of Urology, the Scientific Office of the EAU and the Chairman of the European Section of Female and Functional Urology. Since 2008 he is a principal investigator for the Nijmegen Centre for Molecular Life Sciences. He is an associate editor of Neurourology and Urodynamics and reviewer of several major Urologic Scientific journals. He received about €2.5 million for research grants. He is the author of more than 100 peer-reviewed papers, 5 books and more than 10 book-chapters and books on urological topics.
Dr. Alex Digesu is a Consultant Obstetrician, Gynaecologist & Urogynaecology Subspecialist at St. Mary’s Hospital, London and Honorary Senior Lecturer at the Imperial College, London. Dr. Digesu completed his specialist training in Obstetrics & Gynaecology and Reproductive Medicine in Italy at the University of Bari in 2002. In 2005 he achieved his PhD in Oncological, Gynaecological and Geriatric Surgery from the same university. His clinical and academic experience also includes a five years fellowship in Urogynaecology in London at King’s College Hospital and St. Mary’s Hospital and two years subspecialty training in Urogynaecology & reconstructive pelvic floor surgery at Imperial College of London. Since 2008 Dr Digesu has also worked as Honorary Senior lecturer in Neurourology, at Beata Vergine Hospital in Mendrisio (Switzerland) where sees and treats lower urinary tract disorders (ie incontinence, voiding problems, urinary retention etc) in patients affected by multiple sclerosis and other neurological diseases. Since 2010 Dr Digesu has been accredited by the Royal College of Obstericians and Gynaecologists as a Specialist in Urogynaecology (specialised in treating patients with bladder & bowel problems such as incontinence and uterovaginal prolapse during pregnancy and after childbirth).
Philip E.V. Van Kerrebroeck is Professor of Urology at the University of Maastricht, and works as a urologist at the Maastricht University Medical Centre, the Netherlands. After obtaining his Medical Degree from the University of Louvain, Belgium, he trained in General Surgery and Urology in Belgium, The Netherlands and the USA. He received his Master’s Degree in Medical Sciences from the University of Antwerp, Belgium, and his PhD in Medicine from the Radboud University of Nijmegen, The Netherlands. Professor Van Kerrebroeck has a long-standing clinical interest in different forms of lower urinary tract problems, both in women and men, including neurogenic bladder dysfunction. His research interests include electrical stimulation of the urinary tract, and the development of new therapies in Neuro-Urology and Functional Urology. Professor Van Kerrebroeck was for 8 years Chairman of the Standardisation Committee of the International Continence Society and was first author of the Standardisation report on Nocturia. He is Fellow of the European Board of Urology. He was involved in the New England Research Institutes Interdisciplinary Conferences on Nocturia and is past Chairman of the ICI-RS Nocturia Think Tank. Professor Van Kerrebroeck is a member of 25 scientific societies; he serves on the editorial board of six journals, and has authored over 265 peer-reviewed articles, book chapters and books. He currently serves as a member of the History Office of the EAU.
Dr. Elneil is a Consultant Urogynaecologist and Uro-neurologist at University College Hospital and the National Hospital for Neurology and Neurosurgery in London. At the National Hospital for Neurology and Neurosurgery, she runs the neuromodulation program for bladder and pelvic floor dysfunction, which is used in patients in whom most other treatment modalities have failed.
Over the last decade, Dr. Elneil has developed the field of neuro-urogynaecology. Her research program is focused on the neuropathology of bladder/bowel/pelvic floor dysfunction and the role of innovative therapy in restoring function to these sites. She is also teaching and training junior and senior colleagues in the two specialties in the UK and further afield.
Miss Elneil is the Training Program Director for Urogynaecology at University College London Hospitals, Clinical lead for Uro-neurology training for some UK trainees undertaking the RCOG-accredited subspecialty training program. She is Chair of the RCOG Global Health Program Development Committee, Chair of the IUGA working group on Neuro-urogynaecology and Chronic Pelvic Pain, President of the RSM Pain Council, Author/Editor of the FIGO and partners Fistula training manual and numerous other positions, Member of the ICS Standardization Committee and Member of the EAU Chronic Pelvic Pain Committee.
Dr. Van Buyten received his doctorate in Medical Science, Surgery and Obstetrics from the Free University of Brussels, Belgium in 1980. From 1980 to 1984, he continued his training in anesthesia and intensive care at the University Hospital in Antwerp, Belgium; in pain therapy at the University Hospital in Gent; in neuroanesthesia at CHU Montpellier, France; and in obstetric anesthesia at the CHU Pitie-Salpetriere Paris, France. In 1997, he graduated with a specialized degree in intensive care medicine.
Dr. Van Buyten is currently the Chairman of the Multidisciplinary Pain Center AZ Nikolaas Sint-Niklaas in Belgium. Dr. Van Buyten is a respected and highly sought-after international lecturer on pain management, and is an active researcher in the field. He has been widely published in many scientific journals, is a member in many prestigious scientific societies—including the Belgian Association for Anesthesia-Reanimation, the European Society Regional Anesthesia, the Flemish Pain Society for Anesthesiologists, and the International Neuromodulation Society.
Director of the Pain Research Unit at the Institute of Pain Medicine, Rambam Health Care Campus and a Professor of Neurology and Pain Medicine at the Faculty of Medicine in the Technion - Institute of Technology, Israel.